Travere Therapeutics (Travere Therapeutics) Earnings Yield (Joel Greenblatt) % : -70.42% (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Earnings Yield (Joel Greenblatt) %?

Travere Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $549.8 Mil. Travere Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-387.7 Mil. Travere Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was -70.42%.

The historical rank and industry rank for Travere Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

TVTX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -175.67 Med: -13.64 Max: 36.05
Current: -87.72

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Travere Therapeutics was 36.05%. The lowest was -175.67%. And the median was -13.64%.

TVTX's Earnings Yield (Joel Greenblatt) % is ranked worse than
83.25% of 1403 companies
in the Biotechnology industry
Industry Median: -14.77 vs TVTX: -87.72

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Travere Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

Travere Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Travere Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Travere Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings Yield (Joel Greenblatt) %

Get a 7-Day Free Trial

-30.49

-12.99

-11.96

-24.45

-70.92

Travere Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Earnings Yield (Joel Greenblatt) %	Get a 7-Day Free Trial															-21.10	-31.85	-78.13	-70.92	-70.42

Competitive Comparison of Travere Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Travere Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Travere Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.

Travere Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Travere Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)	=	EBIT	/	Enterprise Value
	=	-364.776	/	515.483229
	=	-70.76 %

Travere Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-387.7 Mil.

Travere Therapeutics (NAS:TVTX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.

Be Aware

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.

Travere Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

Travere Therapeutics (Travere Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Earnings Yield (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130

Website

https://www.travere.com

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Executives

Jula Inrig	officer: Chief Medical Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Peter Heerma	officer: Chief Commercial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote	officer: Senior Vice President, R&D	C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline	officer: Chief Financial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube	director, officer: Chief Executive Officer	3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Elizabeth E Reed	officer: SVP, GC & Corporate Secretary	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Sandra Calvin	officer: VP, Corp Controller and CAO	3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Laura Clague	officer: Chief Financial Officer	370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams	director	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg	officer: Chief Medical Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane	officer: Chief Operating Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Sandra Poole	director	830 WINTER STREET, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066